BMB Reports · 2010 · 32 citations · 18 references
MedicineGeneticsPharmacologyMedical GeneticsPharmacogeneticsPharmacogenomicsChronic Obstructive Pulmonary DiseaseCytochrome P450 EnzymesCytochrome P450-mediated MetabolismDrug Metabolism GeneticsControl Group DesignCyp1a2 Drug MetabolismCytochrome P450 Genetic PolymorphismCytochrome P450 Genotype EffectsCytochrome P450 GenotypingDrug Metabolism PolymorphismsMatched Control GroupTheophylline Therapy
Cytochrome P450 (CYP) 1A2 gene polymorphisms are thought to be involved in the metabolism of theophylline (TP). We aimed to investigate the effect of CYP1A2*1C, CYP1A2*1D, CYP1A2*1E, and CYP1A2*1F polymorphisms of the CYP1A2 on TP metabolism by PCR-RFLP in 100 Turkish patients with chronic obstructive pulmonary disease (COPD) receiving TP. One hundred and one healthy volunteers were included as control group. The genotype frequencies of the CYP1A2*1D and CYP1A2*1F were found to be significantly different in the patients compared to the controls. The "T" allele at -2467 delT and the "C" allele at -163 C > A in the CYP1A2 displayed association with a significantly increased risk for COPD. "T" allele at - 2467 delT was also associated with a high risk of disease severity in COPD. In conclusion, our data suggest that genetic alterations in CYP1A2 may play a role both in the pharmacogenetics of TP and in the development of COPD.
18
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.
Steven G. Potkin, R. Bera, Bala Gulasekaram et al. · PubMed · 1994 · 208 citations
Medicine, Pharmacology, Psychiatry +17
Eleni Aklillu, Juan Antonio Carrillo, Eyasu Makonnen et al. · Molecular Pharmacology · 2003 · 182 citations